Professor Anne-Marie Russell holds a substantive chair in the School of Health Sciences at the University of Birmingham UK. Her primary research interests are in patient centred mixed methods focusing on symptom experiences, supported self-management approaches, and patient reported measures in Interstitial Lung Diseases (ILD). A clinical academic, she works closely with the regional ILD interdisciplinary team at the University Hospitals Birmingham NHS Trust. She is scientific advisory board member of the European Pulmonary fibrosis Foundation and Emeritus board member of the ILD Interdisciplinary Network.

Megan is an NHMRC postgraduate scholar undertaking a PhD looking at the utilisation of a treatable traits model of care in ILD through the University of Sydney. She works as a respiratory specialist in Western Australia.

Gary Anderson works in translational immunopharmacologynusing genetic disease models and clinical cohorts to find molecular mechanisms of lung diseases, especially asthma and COPD. He described the diffusion microkinetic mechanism of long-acting beta-2 agonists and the critical role of IL-4 in murine Th2/T2 lung immunity. In 2008 he proposed the widely adopted “Endotype” concept of disease. His work identified the pathogenic role of SAA, gp130 and the Src family kinases LYN and HCK in lung disease. Earlier, he worked in the Swiss pharma industry and contributed to the discovery and development of the clinical medicines formoterol, indacaterol, omalizumab/anti-IgE and imatininb. His current work on drug development includes otilimab/anti-GM-CSF, elarekibep/PRS-060/AZD1472 anticalin and new inhaled JAG-1 blockers for muco-obstructive disease. He was a co-author of the Lancet Commission on asthma and leads the CURE Asthma initiative.